Lectures and seminars Seminar: “Dark” Pathways of Protein Transnitrosylation Mediate Synapse Loss in Alzheimer’s Disease: Mechanism and Potential Treatment
Welcome to the seminar with Stuart A. Lipton, MD, PhD.
Professor and Founding Director, Neurodegeneration New Medicines Center; Step Family Foundation Endowed Chair,
Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California.
Professor Lipton described the mechanism of action and contributedto the clinical development of the approved Alzheimer’s drug memantine. He also discovered the posttranslational redox modification known as protein S-nitrosylation.
Recently, Lipton and colleagues combined memantine with S-nitrosylation chemistry to produce a new drug called NitroSynapsin, which displays disease-modifying activity in animal models of Alzheimer's disease, both protecting synapses and improving neurobehavioral deficits.